Next Article in Journal
Integrated Exposure-Based Therapy for Co-Occurring Post Traumatic Stress Disorder (PTSD) and Substance Dependence: Predictors of Change in PTSD Symptom Severity
Previous Article in Journal
An Admission-to-Discharge BNP Increase Is a Predictor of Six-Month All-Cause Death in ADHF Patients: Inferences from Multivariate Analysis Including Admission BNP and Various Clinical Measures of Congestion
Previous Article in Special Issue
Advances in Radiotherapy Management of Esophageal Cancer
Open AccessReview

The Future Prospects of Immune Therapy in Gastric and Esophageal Adenocarcinoma

1
Department of Hematology and Oncology, Winship Cancer Institute, Emory University, 1365 Clifton Rd NE, Atlanta, GA 30322, USA
2
Department of Medicine, Balamand University, Beirut 1300, Lebanon
3
Department of Internal Medicine, Emory University, Atlanta, GA 30322, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Samuel C. Mok
J. Clin. Med. 2016, 5(11), 100; https://doi.org/10.3390/jcm5110100
Received: 4 August 2016 / Revised: 2 November 2016 / Accepted: 2 November 2016 / Published: 14 November 2016
(This article belongs to the Special Issue Updates on Treatment of Esophageal Cancer)
The prognosis of esophageal cancers is poor and novel approaches are urgently needed. Despite improvements in outcomes with transtuzumab and ramucirumab, these improvements added an average of only 2 to 3 months with a median overall survival reported to be around 1 year. Comprehensive genomic sequencing has defined some molecular alterations with potential targets, but the majority of patients still do not benefit from druggable targets. Breakthroughs in immune checkpoint blockade have provided new therapeutic options in many cancers. Programmed death ligand 1 (PDL1) overexpression, a possible biomarker predicting response to immune checkpoint inhibitors, approaches forty percent in esophageal and gastric cancers. Translational and molecular studies have shown that esophageal cancers are possible candidate malignancies for immune checkpoint inhibition. In this review, we plan to highlight the mechanisms, preclinical, and early clinical data that provide insight on the role of immune therapeutics in esophageal cancers. View Full-Text
Keywords: esophageal cancer; immune therapy; progress esophageal cancer; immune therapy; progress
Show Figures

Graphical abstract

MDPI and ACS Style

Shaib, W.L.; Nammour, J.P.A.; Gill, H.; Mody, M.; Saba, N.F. The Future Prospects of Immune Therapy in Gastric and Esophageal Adenocarcinoma. J. Clin. Med. 2016, 5, 100.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop